AstraZeneca (AZN) Posts Light Q4 EPS Results; Revs Top Views

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.16, $0.40 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $8.66 billion versus the consensus estimate of $8.59 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Medtronic completes $550 million Scientia Vascular acquisition